...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy
【24h】

A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy

机译：奥曲肽与最佳支持治疗的随机试验仅在化疗难以治疗的晚期胃肠道癌症患者中进行

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Octreotide, a somatostatin analogue, has been shown to inhibit the growth of gastrointestinal cancers in vitro and in vivo. To assess the anti-tumour effect of octreotide, we performed a randomised trial comparing octreotide with best supportive care in advanced gastrointestinal cancer patients refractory to chemotherapy. A total of 107 patients with advanced gastrointestinal cancer refractory to chemotherapy were randomised to receive octreotide at the dose of 200 micrograms three times a day for 5 days a week, or the best supportive care only. The primary outcome variable was the survival duration. Response rate was an outcome variable of secondary importance. Fifty-five patients (15 stomach, 16 pancreas, 24 colon-rectum) received octreotide, while 52 (14 stomach, 16 pancreas, 22 colon-rectum) received the best supportive care. Patients treated with octreotide had a significant advantage in duration of survival with a median survival time of 20 weeks vs 11 in the control group (P < 0.0001). This advantage was present also considering the survival data for each tumour group. Twenty-five patients (45%) given octreotide showed stable disease vs only eight (15%) in the control group (P < 0.001). In conclusion, octreotide therapy seems to confer a survival benefit in advanced gastrointestinal cancer patients refractory to chemotherapy. Additional studies will be needed to confirm these results and to clarify other questions about dose and schedule of octreotide.
机译：已显示生长抑素类似物奥曲肽在体外和体内抑制胃肠道癌的生长。为了评估奥曲肽的抗肿瘤作用，我们进行了一项随机试验，比较了奥曲肽与难治性化疗的晚期胃肠道癌症患者的最佳支持治疗。总共107例对化疗难治的晚期胃肠道癌患者被随机分配为接受奥曲肽，剂量为200微克，一周3天，每天3次，或仅采用最佳支持治疗。主要结果变量是生存期。回应率是次要重要性的结果变量。 55名患者（15胃，16胰腺，24结肠直肠）接受了奥曲肽，而52名患者（14胃，16胰腺，22结肠直肠）接受了最好的支持治疗。用奥曲肽治疗的患者在生存期方面具有显着优势，中位生存时间为20周，而对照组为11个（P <0.0001）。考虑到每个肿瘤组的存活数据，也存在该优点。服用奥曲肽的患者有25名（45％）表现出稳定的疾病，而对照组中只有8名（15％）（P <0.001）。总之，奥曲肽治疗似乎可以使难于化疗的晚期胃肠道癌症患者受益。需要进一步的研究来证实这些结果，并阐明有关奥曲肽剂量和给药方案的其他问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号